Literature DB >> 8482186

Effect of erythromycin on interdigestive gastrointestinal contractile activity and plasma motilin concentration in humans.

O Kawamura1, T Sekiguchi, M Kusano, T Nishioka, Z Itoh.   

Abstract

The effects of erythromycin (EM) on gastrointestinal contractile activity during the interdigestive period were investigated in seven healthy subjects using an infused catheter system, and the changes in the plasma motilin concentration were also determined. Graded EM doses (0.1-1.5 mg/kg) were administered intravenously over 5 min, usually during gastric phase I. EM induced interdigestive migrating contractions (IMCs). Their induction rate was low after low doses of EM, but gradually increased as the dose increased to reach 71.4% at an EM dose of 0.375 mg/kg. Strong contractions, which were quite similar to phase III activity of the stomach but did not migrate or migrated incompletely to the duodenum, were observed at EM doses above 0.375 mg/kg. Therefore, the optimum dose of EM for inducing an IMC was established to be 0.375 mg/kg. In comparison with spontaneous IMCs, EM-induced IMCs had a significantly longer duration in the stomach and a significantly lower amplitude in the duodenum. These observations indicate that EM induced phase III activity more intensively in the stomach than in the duodenum. The plasma motilin concentration increased significantly during EM-induced IMCs, and this suggested a close relationship between this hormone and induction of the IMC. The increase in motilin levels was also observed of the strong gastric contractions which did not migrate or migrated incompletely to the duodenum. Therefore, it seems reasonable to suggest that motilin is involved in phase III activity of the stomach rather than in that of the duodenum.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482186     DOI: 10.1007/bf01295913

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  The interdigestive myo-electric complex of the stomach and small bowel of dogs.

Authors:  C F Code; J A Marlett
Journal:  J Physiol       Date:  1975-03       Impact factor: 5.182

2.  In man, only activity fronts that originate in the stomach correlate with motilin peaks.

Authors:  V Bormans; T L Peeters; J Janssens; D Pearce; M Vandeweerd; G Vantrappen
Journal:  Scand J Gastroenterol       Date:  1987-09       Impact factor: 2.423

3.  Gastrointestinal motor effects of erythromycin.

Authors:  M F Otterson; S K Sarna
Journal:  Am J Physiol       Date:  1990-09

4.  Pancreatic polypeptide and intestinal migrating motor complex in humans. Effect of pancreaticobiliary secretion.

Authors:  C Owyang; S R Achem-Karam; A I Vinik
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

5.  Changes in plasma motilin concentration and gastrointestinal contractile activity in conscious dogs.

Authors:  Z Itoh; S Takeuchi; I Aizawa; K Mori; T Taminato; Y Seino; H Imura; N Yanaihara
Journal:  Am J Dig Dis       Date:  1978-10

6.  Fasting plasma motilin levels are related to the interdigestive motility complex.

Authors:  T L Peeters; G Vantrappen; J Janssens
Journal:  Gastroenterology       Date:  1980-10       Impact factor: 22.682

7.  [Effects of cisapride on lower esophageal sphincter pressure and gastroduodenal motor activity in man].

Authors:  T Nishioka; T Sekiguchi; M Machida; M Kusano; M Kogure; T Matsuzaki; R Katoh; T Horikoshi; H Fukagawa; H Tajima
Journal:  Nihon Heikatsukin Gakkai Zasshi       Date:  1986-04

8.  Effect of rabbit antimotilin serum on myoelectric activity and plasma motilin concentration in fasting dog.

Authors:  K Y Lee; T M Chang; W Y Chey
Journal:  Am J Physiol       Date:  1983-10

9.  Erythromycin induces migrating motor complex in human gastrointestinal tract.

Authors:  T Tomomasa; T Kuroume; H Arai; K Wakabayashi; Z Itoh
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

10.  Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut.

Authors:  Z Itoh; T Suzuki; M Nakaya; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

View more
  8 in total

1.  Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients.

Authors:  T A McNearney; H S Sallam; S E Hunnicutt; D Doshi; D E Wollaston; M D Mayes; J D Z Chen
Journal:  Neurogastroenterol Motil       Date:  2009-06-30       Impact factor: 3.598

2.  Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings.

Authors:  F Caron; M Bouaniche; F Delatour; P Ducrotte; J C Torlotin; P Denis; G Humbert; B Rouveix
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 3.  Equine gastrointestinal motility--ileus and pharmacological modification.

Authors:  Judith Koenig; Nathalie Cote
Journal:  Can Vet J       Date:  2006-06       Impact factor: 1.008

4.  Effect of erythromycin derivative EM523L on human interdigestive gastrointestinal tract.

Authors:  O Kawamura; T Sekiguchi; Z Itoh; S Omura
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

5.  The denervated stomach as an esophageal substitute is a contractile organ.

Authors:  J M Collard; R Romagnoli; J B Otte; P J Kestens
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

6.  Erythromycin enhances early postoperative contractility of the denervated whole stomach as an esophageal substitute.

Authors:  J M Collard; R Romagnoli; J B Otte; P J Kestens
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

7.  Oral erythromycin accelerates impaired gastrointestinal motility after endoscopic mucosal resection.

Authors:  Osamu Kawamura; Motoyasu Kusano; Yasuyuki Shimoyama; Tsutomu Horikoshi; Toshikazu Sekiguchi; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

8.  Erythromycin versus metoclopramide for post-pyloric spiral nasoenteric tube placement: a randomized non-inferiority trial.

Authors:  Bei Hu; Xin Ouyang; Liming Lei; Cheng Sun; Ruibin Chi; Jian Guo; Wenlong Guo; Yanlin Zhang; Yong Li; Daoyong Huang; Huafeng Sun; Zhiqiang Nie; Jieyang Yu; Yuan Zhou; Hao Wang; Jinhe Zhang; Chunbo Chen
Journal:  Intensive Care Med       Date:  2018-11-21       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.